Effecting Change in Glioblastoma
August 20, 2015 – Dellann Elliott Mydland
Bookshelf: Surviving Cancer: Our Voices & Choices
August 27, 2015 – Marion Behr
Diagnosis on a Chip? No Longer Science Fiction
August 27, 2015 – Len Lichtenfeld
Healing in the Key of C: Joy in Music for Cancer Survivors
August 26, 2015 – Khevin Barnes
First Line: Taylor Swift Donates $50,000 to Help Fan Fund Cancer Treatment
August 26, 2015 – Beth Fand Incollingo
Pneumonitis: A Delayed Reaction
August 25, 2015
A Cultural and Scientific Tug of War
August 25, 2015 – Debu Tripathy
Giving Caregivers a Hand
August 25, 2015 – Melissa Silverberg
Time Management Techniques for Caregivers
August 25, 2015 – Melissa Silverberg
Keeping the World in World-Class Cancer Care
August 24, 2015 – Mike Hennessy, Sr.
Comments From Readers
August 24, 2015
Medical Marijuana: Smoking Out the Evidence
August 24, 2015 – Andrew Smith
Patients Unable to Work May Qualify for Disability Benefits
August 21, 2015 – Deanna Power
New Treatments May Be Worth the Wait in CLL
August 21, 2015 – Erik Ness
For Survivors of Cancer, Finding Love Involves an Extra Hurdle
August 21, 2015
Non-Physician Practitioners Playing Larger Roles in Cancer Care
August 20, 2015 – Melissa Quintero
In the Spotlight: Young-Adult Cancer
August 19, 2015
Supporting Teens and Young Adults Through Cancer
August 19, 2015 – Deborah Bell
Can a Low-Acid Diet Help Prevent Cancer?
August 18, 2015 – Dara Chadwick
Delayed Reaction
August 05, 2015 – Jodi Helmer
Effecting Change in Glioblastoma
August 20, 2015 – Dellann Elliott Mydland
Bookshelf: Surviving Cancer: Our Voices & Choices
August 27, 2015 – Marion Behr
Diagnosis on a Chip? No Longer Science Fiction
August 27, 2015 – Len Lichtenfeld
Healing in the Key of C: Joy in Music for Cancer Survivors
August 26, 2015 – Khevin Barnes
First Line: Taylor Swift Donates $50,000 to Help Fan Fund Cancer Treatment
August 26, 2015 – Beth Fand Incollingo
Currently Viewing
Pneumonitis: A Delayed Reaction
August 25, 2015
Giving Caregivers a Hand
August 25, 2015 – Melissa Silverberg
Time Management Techniques for Caregivers
August 25, 2015 – Melissa Silverberg
Keeping the World in World-Class Cancer Care
August 24, 2015 – Mike Hennessy, Sr.
Comments From Readers
August 24, 2015
Medical Marijuana: Smoking Out the Evidence
August 24, 2015 – Andrew Smith
Patients Unable to Work May Qualify for Disability Benefits
August 21, 2015 – Deanna Power
New Treatments May Be Worth the Wait in CLL
August 21, 2015 – Erik Ness
For Survivors of Cancer, Finding Love Involves an Extra Hurdle
August 21, 2015
Non-Physician Practitioners Playing Larger Roles in Cancer Care
August 20, 2015 – Melissa Quintero
In the Spotlight: Young-Adult Cancer
August 19, 2015
Supporting Teens and Young Adults Through Cancer
August 19, 2015 – Deborah Bell
Can a Low-Acid Diet Help Prevent Cancer?
August 18, 2015 – Dara Chadwick
Delayed Reaction
August 05, 2015 – Jodi Helmer
A Country Mile: Patients in Rural Areas Face Barriers to Treatment
August 18, 2015 – Don Vaughan

Pneumonitis: A Delayed Reaction

Pneumonitis, a lung inflammation, often appears months after the cancer treatment that sparked it.
PUBLISHED August 25, 2015
Pneumonitis, a noninfectious inflammation of the lungs, is a side effect associated with several cancer treatments, including radiation and chemotherapy as well as newer targeted drugs and immunotherapies. The symptoms range from mild to severe respiratory symptoms but may not appear until weeks to months into treatment — and sometimes long after treatments end — leading to frequent misdiagnoses, particularly because the symptoms resemble those of pneumonia.

Causes

When sparked by cancer therapies, the underlying causes and frequency of pneumonitis are specific to the type of treatment.

Several chemotherapy medications, including bleomycin, Busulfex (busulfan), cyclophosphamide, BiCNU (carmustine), the taxanes and methotrexate, can cause inflammation in the alveoli, the small air sacs in the lungs, filling them with white blood cells and fluid.

Radiation that targets the lungs and chest, including treatments for lung or breast cancer, is the main cause of radiation pneumonitis. Radiation reduces the production of surfactant, a substance that keeps the lungs expanded during exhalation, increasing the surface area available for the exchange of oxygen and carbon dioxide; without sufficient surfactant, gas exchange is compromised.

Targeted cancer drugs — in particular mTOR inhibitors for renal cancer or drugs targeting EGFR — as well as immunotherapies such as CTLA4 or PD-1/PD-L1 inhibitors for melanoma or lung cancers, are also associated with pneumonitis, although the exact mechanism is unknown. These tend to resolve with discontinuation of the drug.

Between 10 and 20 percent of patients undergoing chemotherapy or radiation develop pneumonitis. One 2015 study of mTOR inhibitors published in Oncologist found that 58 percent of patients taking the drugs for Waldenström macroglobulinemia were diagnosed with pneumonitis; a 2015 review of the medical literature, published in Current Oncology, found that noninfectious pneumonitis was diagnosed in 15 percent of breast cancer patients who took the mTOR inhibitor Afinitor (everolimus).

Since targeted drugs and immunotherapies are newer, only a few small studies have explored the incidence of pneumonitis. Research published in 2012 in the New England Journal of Medicine found that just 3 percent of patients receiving anti-PD-1 antibodies for melanoma, prostate, renal, colorectal and non-small-cell lung cancers developed pneumonitis.

Symptoms

The hallmark symptoms of pneumonitis include shortness of breath, dry cough, low-grade fever, chest tightness and/or pain and general malaise. For pneumonitis attributed to radiation and chemotherapy, the symptoms, which can range from mild to severe, generally appear between one and six months after treatment. One study found that patients taking PD-1 inhibitors reported symptoms an average of nine weeks after the drug therapy was initiated.

Diagnosis and Treatment

Pneumonitis is a clinical diagnosis; there is no specific diagnostic test available.

Doctors frequently detect abnormalities via chest Xray or CT scan, often in the absence of any symptoms. Inflammation triggered by chemotherapy drugs is more diffuse and tends to appear in multiple lobes of the lung or both lungs. In comparison, radiation pneumonitis is focal, often limited to the area of radiation and around the radiation port.

Doctors may also order blood work to look for signs of inflammation, including increased white blood cell count and elevated sedimentation rates. Bacterial and viral cultures may also be analyzed to exclude infectious pneumonia.

The treatment protocol is designed to reduce inflammation. A prolonged course of steroids such as prednisone (often taken for up to 10 weeks with the dosage tapered over time) can ease inflammation and clear up pneumonitis.

With treatment, most patients achieve complete recovery from their symptoms, but a diagnosis of pneumonitis does increase the risk of developing subsequent pulmonary complications, including fibrosis, a permanent scarring of the lungs. The effects can be lasting and include long-term shortness of breath, along with increased risk of pulmonary exacerbations and infections. Some treatments, such as radiation and bleomycin, are associated with longer-term or permanent effects. In rare cases, pneumonitis-related deaths have been reported among patients receiving EGFRtargeting drugs or anti-PD-1 antibodies.

If significant pneumonitis is diagnosed during the course of immunotherapy or targeted drug therapies, treatment may be discontinued. In less severe cases, the drugs may be held at their current dose until the side effect is mitigated.

Risk Factors

There are several factors that increase the risk of developing pneumonitis.

The most common risk factor is related to treatment protocols. Rates of pneumonitis are higher among patients who receive combination radiation and chemotherapy treatments, particularly those that include a taxane (Taxol or Taxotere), regardless of whether the radiation and chemotherapy are concurrent or sequential.

The dose of radiation and amount of tissue being irradiated are also predictors of risk; the more tissue being treated and the higher the dose of radiation, the higher the risk of pneumonitis.

Other risk factors for developing pneumonitis include pre-existing lung diseases such as emphysema and COPD and exposure, often occupational, to toxic allergens, including fungus spores and bird droppings.

Prior to treatment, doctors may perform pulmonary function tests to determine whether the lungs can handle the additional stress of therapies such as radiation and chemotherapy.

Incidence Reduction

For patients who undergo radiation, there are strategies to reduce the risk of pneumonitis.

Newer modalities of radiation therapy, including Intensity-Modulated Radiation Therapy (IMRT), Image-Guided Radiation Therapy (IGRT) and Stereotactic Body Radiation Therapy (SBRT), were designed to better target the treatment region and reduce the amount of radiation scatter, which, in turn, minimizes the amount of radiation exposure to the normal tissues.

Patients taking other types of therapies should rely on their doctors to monitor them for pneumonitis, reporting any potential symptoms of the condition.
Continue the conversation on CURE’s forum. >>
Talk about this article with other patients, caregivers, and advocates in the General Discussions CURE discussion group.

Related Articles

1
×

Sign In

Not a member? Sign up now!
×

Sign Up

Are you a member? Please Log In